Urodynamics assessment in patients with multiple sclerosis

多发性硬化症患者的尿动力学评估

阅读:3

Abstract

OBJECTIVES: The aim of this study is to review initial urodynamics (UDS) findings in patients with multiple sclerosis (MS) related lower urinary tract symptoms, establish where UDS happen in treatment pathways and to evaluate the benefit of video over standard UDS. PATIENTS AND METHODS: OnaBotulinumToxin A (BTX-A) naïve, MS patients who had undergone UDS were identified from prospectively maintained databases from UK hospitals. RESULTS: One hundred fifty-seven patients were identified from seven UK departments. One (0.9%) female patient and 3 (6.7%) males had end fill pressures > 40 cmH(2)O. No female and two (5.1%) males showed vesico-ureteric reflux. Of female patients reporting pure overactive bladder (OAB) symptoms, 61 (67.2%) showed neurogenic detrusor overactivity (NDO), 10 (11.1%) showed loss of compliance (LoC) and 28 (31.1%) showed no NDO or LoC. Following UDS, 134 (85.4%) patients underwent management changes: 61 (72.6%) females and 25 (78.1%) males were offered non-medical treatment, oral or topical medication; 30 (30.9%) females and 7 (18.9%) males were advised to start self-catheterisation; 16 (19.0%) females and 4 (12.5%) males were offered intra-vesical BTX-A; two (2.4%) females were offered SUI surgery and one (3.1%) male was offered bladder outflow obstruction surgery. CONCLUSION: Many patients underwent UDS prior to conservative and medical management, which is earlier than most guidelines recommend, potentially delaying non-invasive treatment. This study supports the need for VUDS at initial assessment of men with MS. Standard UDS suffice in women with MS and pure OAB symptoms unresponsive to conservative measures and oral medication unless they have abnormal renal function, hydronephrosis or significant post void volumes.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。